Syncom Formulations Shares Surge on Bullish Technical Momentum and Upgraded Rating

Price Momentum and Market Performance

On 31 Aug 2026, Syncom Formulations closed at ₹19.46, up from the previous close of ₹17.35, marking a robust intraday gain of 12.16%. The stock touched its 52-week high of ₹20.35 during the session, signalling renewed buying interest. This performance contrasts sharply with the broader market, as the Sensex recorded a marginal decline of 0.36% over the past week, while Syncom surged 20.57% in the same period.

Over longer horizons, the stock has outperformed the benchmark significantly. Year-to-date returns stand at 36.37%, compared to a Sensex decline of 9.34%. Over one year, Syncom has delivered 14.88% gains versus a 3.52% loss for the Sensex. The outperformance is even more pronounced over three, five, and ten-year periods, with returns of 121.89%, 204.54%, and an impressive 642.75%, respectively, dwarfing the Sensex’s corresponding returns of 18.87%, 37.67%, and 178.11%.

Technical Indicator Analysis

The recent upgrade in Syncom’s technical trend from mildly bullish to bullish is supported by a confluence of positive signals across multiple timeframes and indicators. The Moving Average Convergence Divergence (MACD) indicator is bullish on both weekly and monthly charts, signalling sustained upward momentum. This is complemented by bullish Bollinger Bands on the same timeframes, indicating price strength and potential continuation of the rally.

Daily moving averages also confirm the bullish trend, with the stock price trading above key averages, reinforcing short-term strength. The On-Balance Volume (OBV) indicator is bullish on weekly and monthly charts, suggesting that volume supports the price advances, a critical factor for validating trend sustainability.

However, not all indicators are uniformly positive. The Relative Strength Index (RSI) remains bearish on weekly and monthly charts, indicating that the stock may be approaching overbought territory or facing some short-term selling pressure. Similarly, the Know Sure Thing (KST) indicator is bullish on the weekly chart but bearish on the monthly, reflecting some divergence in momentum across timeframes.

The Dow Theory assessment remains mildly bullish on both weekly and monthly scales, suggesting that while the overall trend is positive, caution is warranted as the market digests recent gains.

Mojo Score and Grade Upgrade

MarketsMOJO has upgraded Syncom Formulations’ Mojo Grade from Sell to Hold as of 24 Aug 2026, reflecting a Mojo Score of 65.0. This upgrade signals a shift in the stock’s quality and momentum metrics, suggesting that while the stock is not yet a strong buy, it has moved out of the sell territory and is now considered a hold. The micro-cap classification highlights the stock’s smaller market capitalisation, which often entails higher volatility but also greater upside potential for discerning investors.

The upgrade is consistent with the technical improvements observed, including the bullish MACD and moving averages, and the positive volume trends. Investors should note, however, that the bearish RSI and mixed KST readings counsel prudence and suggest monitoring for potential short-term pullbacks.

Comparative Sector and Industry Context

Operating within the Pharmaceuticals & Biotechnology sector, Syncom Formulations is positioned in an industry known for innovation and growth potential. The sector has seen varied performance in recent months, with some stocks experiencing volatility due to regulatory developments and global supply chain challenges. Syncom’s strong technical rebound and outperformance relative to the Sensex indicate resilience and potential leadership within its peer group.

Investors analysing Syncom should consider the broader sector dynamics alongside the company’s technical signals. The bullish weekly and monthly Bollinger Bands and OBV suggest that the stock is attracting accumulation, which could be a precursor to further gains if sector tailwinds persist.

Risk Considerations and Outlook

Despite the encouraging technical signals, the bearish RSI on weekly and monthly charts warns of possible overextension in the near term. This could lead to profit-taking or consolidation before the next leg higher. The mixed KST readings reinforce this view, indicating that momentum is not uniformly strong across all timeframes.

Given the stock’s micro-cap status, investors should also be mindful of liquidity risks and potential volatility. The recent price surge of over 12% in a single day exemplifies this risk-reward dynamic. A disciplined approach, incorporating stop-loss levels and monitoring of volume trends, is advisable.

Conclusion: Technical Upgrade Signals Cautious Optimism

Syncom Formulations (India) Ltd’s recent technical parameter changes reflect a meaningful shift in price momentum and investor sentiment. The upgrade from mildly bullish to bullish technical trend, supported by strong MACD, moving averages, Bollinger Bands, and OBV readings, suggests that the stock is poised for further gains in the medium term.

However, the bearish RSI and mixed KST indicators counsel caution, signalling that short-term corrections or consolidation phases may occur. The MarketsMOJO upgrade to a Hold rating aligns with this balanced outlook, recommending investors to maintain positions while monitoring key technical levels closely.

With a current price near its 52-week high and significant outperformance relative to the Sensex over multiple timeframes, Syncom remains an intriguing micro-cap stock within the Pharmaceuticals & Biotechnology sector. Investors should weigh the technical momentum against inherent risks and sector dynamics to make informed decisions.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today